Potential Effects of Aspirin on Lysosomal Biogenesis and Amyloid-β Clearance: An Old Drug and Novel Insights in Alzheimer's Disease Therapy.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 6 citations in OpenAlex.

1. Aspirin Use on Incident Dementia and Mild Cognitive Decline: A Systematic Review and Meta-Analysis.Frontiers in aging neuroscience · 2020
   Pooled it
2. Advances in Alzheimer's disease: mechanistic insights and therapeutic targets.Science China. Life sciences · 2026
   Review
3. Targeting memory loss with aspirin, a molecular mechanism perspective for future therapeutic approaches.Inflammopharmacology · 2023
   Review
4. Analysis of Serum miRNAs in Alzheimer's Disease.American journal of Alzheimer's disease and other dementias
   Article

Corrections and comments

• Comment on
  Aspirin Induces Lysosomal Biogenesis and Attenuates Amyloid Plaque Pathology in a Mouse Model of Alzheimer's Disease via PPARα.2018

Authors and funding

1 author at 1 institution in 1 country.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as